{
    "clinical_study": {
        "@rank": "161269", 
        "arm_group": [
            {
                "arm_group_label": "MK-1029 10 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "MK-1029 30 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "MK-1029 60 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "MK-1029 150 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Montelukast 10 mg", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "MK-1029 1 mg or 3 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Montelukast 10 mg + MK-1029", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this adaptive-design study is to evaluate the dose-related effectiveness and\n      safety of MK-1029, alone or in combination with montelukast, compared to placebo and to\n      montelukast alone, in the treatment of persistent asthma in adults."
        }, 
        "brief_title": "A Dose-Ranging Study of MK-1029 in Adults With Persistent Asthma (MK-1029-012 AM2)", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  not pregnant or breastfeeding, and not planning to become pregnant during the study\n\n          -  history of symptoms of persistent asthma for at least one year\n\n          -  current use of acceptable asthma treatments and willingness to taper or discontinue\n             these treatments; acceptable asthma treatments:\n\n               -  use of inhaled SABAs (e.g., albuterol/salbutamol) only \"as-needed\" with no use\n                  of asthma controller medications; OR\n\n               -  use of stable doses of low- or medium-dose inhaled corticosteroids (ICS), alone,\n                  or in combination with either a long-acting beta-agonist (LABA) or other asthma\n                  controller medications (including leukotriene receptor antagonists) and can\n                  tolerate tapering or discontinuation\n\n          -  no history of smoking OR no smoking within <1 year with a smoking history of \u226410\n             pack-years\n\n          -  ability to maintain a constant day/night, awake/sleep cycle\n\n          -  agreement to not change habitual consumption of beverages or food containing caffeine\n             throughout the study\n\n          -  Body Mass Index (BMI) of 15 to 40 kg/m^2\n\n        Exclusion Criteria:\n\n          -  myocardial infarction, congestive heart failure, or uncontrolled cardiac arrhythmia\n             within past \u22643 months\n\n          -  hospitalization within past \u22644 weeks\n\n          -  major surgical procedure within past \u22644 weeks\n\n          -  participation in a clinical study involving an investigational drug within past \u22644\n             weeks\n\n          -  current regular use or recent (within past \u22645 years) past abuse of alcohol (>14\n             drinks/week) or illicit drugs\n\n          -  donation of a unit of blood within past \u22642 weeks or intention to donate a unit of\n             blood during the study\n\n          -  evidence of another clinically significant, active pulmonary disorder such as chronic\n             obstructive pulmonary disease (COPD)\n\n          -  emergency room treatment for asthma within past \u22644 weeks or hospitalization for\n             asthma within past \u22648 weeks\n\n          -  respiratory tract infection requiring antibiotic treatment within past \u22648 weeks\n\n          -  evidence of active, clinically significant sinus disease within past \u22641 week\n\n          -  history of a clinically significant psychiatric disorder, other than stable\n             depression, within past \u226412 weeks\n\n          -  history of HIV\n\n          -  hypersensitivity or intolerance to inhaled beta-agonists, leukotriene antagonists,\n             leukotriene synthesis inhibitors, or any of their ingredients, including lactose and\n             galactose\n\n          -  clinically unstable disease of the ophthalmologic, neurological, hepatic, renal,\n             connective tissue, genitourinary, gastrointestinal, cardiovascular or hematologic\n             systems\n\n          -  current cancer or history (within past \u22645 years) of cancer (except for successfully\n             treated basal and squamous cell carcinomas of the skin); if cancer-free for >5 years,\n             study participation may be allowed\n\n          -  evidence of uncontrolled hypertension"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1475", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01656395", 
            "org_study_id": "1029-012", 
            "secondary_id": "2012-000643-27"
        }, 
        "intervention": [
            {
                "arm_group_label": "MK-1029 10 mg", 
                "description": "Parts I-II:  Participants will receive MK-1029 10 mg tablets taken once daily (QD)", 
                "intervention_name": "MK-1029 10 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MK-1029 30 mg", 
                    "MK-1029 60 mg"
                ], 
                "description": "Parts I-II:  Participants will receive MK-1029 30 mg tablets QD", 
                "intervention_name": "MK-1029 30 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MK-1029 150 mg", 
                "description": "Parts I-II:  Participants will receive MK-1029 150 mg tablets QD", 
                "intervention_name": "MK-1029 150 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Montelukast 10 mg", 
                "description": "Parts I-II:  Participants will receive Montelukast 10 mg tablets QD", 
                "intervention_name": "Montelukast 10 mg", 
                "intervention_type": "Drug", 
                "other_name": "SINGULAIR\u00ae"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Parts I-II: Participants will receive Placebo tablets QD", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MK-1029 1 mg or 3 mg", 
                "description": "Part II: Participants will receive either MK-1029 1 mg or 3 mg tablets (dose to be determined based on results of interim analysis from Part I) QD.", 
                "intervention_name": "MK-1029 1 mg or 3 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Montelukast 10 mg + MK-1029", 
                "description": "Part II: Participants will receive Montelukast 10 mg tablets QD and MK-1029 tablets (dose to be determined based on results of interim analysis from Part I) QD", 
                "intervention_name": "Montelukast 10 mg + MK-1029", 
                "intervention_type": "Drug", 
                "other_name": "SINGULAIR\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Montelukast"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Mesa", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85206"
                    }, 
                    "name": "Call for Information (Investigational Site 0045)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21236"
                    }, 
                    "name": "Call for Information (Investigational Site 0170)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97202"
                    }, 
                    "name": "Call for Information (Investigational Site 0061)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Call for Information (Investigational Site 0062)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boerne", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78006"
                    }, 
                    "name": "Call for Information (Investigational Site 0148)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78249"
                    }, 
                    "name": "Call for Information (Investigational Site 9180)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Waco", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76712"
                    }, 
                    "name": "Call for Information (Investigational Site 0038)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Medical Information Centre / Centre de l'information medicale de Merck Canada", 
                    "phone": "514-428-8600 / 1-800-567-2594"
                }, 
                "facility": {
                    "address": {
                        "city": "Kirkland", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H9H 3L1"
                    }, 
                    "name": "Merck Canada"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Maria Elena Azara Hernandez", 
                    "phone": "56 2 6558958"
                }, 
                "facility": {
                    "address": {
                        "city": "Santiago", 
                        "country": "Chile"
                    }, 
                    "name": "Merck Sharp & Dohme (I.A.) Corp."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Francesca Carvajal", 
                    "phone": "57 1219109011090"
                }, 
                "facility": {
                    "address": {
                        "city": "Bogota", 
                        "country": "Colombia"
                    }, 
                    "name": "MDS Colombia SAS"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dominique Blazy", 
                    "phone": "33 147548990"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "MSD France"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "German Medical Information Center", 
                    "phone": "49 800 673 673 673"
                }, 
                "facility": {
                    "address": {
                        "city": "Haar", 
                        "country": "Germany"
                    }, 
                    "name": "Merck Sharp & Dohme GmbH"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Soraya Cedraro", 
                    "phone": "507-282-7200"
                }, 
                "facility": {
                    "address": {
                        "city": "Guatemala", 
                        "country": "Guatemala"
                    }, 
                    "name": "MSD CARD"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Patrizia Nardini", 
                    "phone": "39 06 361911"
                }, 
                "facility": {
                    "address": {
                        "city": "Rome", 
                        "country": "Italy"
                    }, 
                    "name": "MSD Italia S.r.l."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Japan Call Center", 
                    "phone": "81-3-6272-1957"
                }, 
                "facility": {
                    "address": {
                        "city": "Chiyoda-Ku, Tokyo", 
                        "country": "Japan", 
                        "zip": "102-8667"
                    }, 
                    "name": "MSD K.K."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Oscar Espinoza", 
                    "phone": "(51-1) 411-5100"
                }, 
                "facility": {
                    "address": {
                        "city": "Lima", 
                        "country": "Peru"
                    }, 
                    "name": "Merck Sharp & Dohme, Peru S.R.L."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Felipe Arbelaez", 
                    "phone": "(787) 474-8200"
                }, 
                "facility": {
                    "address": {
                        "city": "Carolina", 
                        "country": "Puerto Rico"
                    }, 
                    "name": "Merck Sharp & Dohme (I.A.) Corp."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Khanyi Mzolo", 
                    "phone": "27 11 655 3140"
                }, 
                "facility": {
                    "address": {
                        "city": "Midrand", 
                        "country": "South Africa"
                    }, 
                    "name": "MSD (Pty) LTD South Africa"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Paul Robinson", 
                    "phone": "44 1992452396"
                }, 
                "facility": {
                    "address": {
                        "city": "Hoddesdon", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Merck Sharp & Dohme Ltd."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "Chile", 
                "Colombia", 
                "France", 
                "Germany", 
                "Guatemala", 
                "Italy", 
                "Japan", 
                "Peru", 
                "Puerto Rico", 
                "South Africa", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "8", 
        "official_title": "A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Adaptive-Design, Dose-Ranging Study of MK-1029 in Adult Subjects With Persistent Asthma", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Average Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and last six weeks of treatment"
            }, 
            {
                "measure": "Percentage of Participants Who Experience Adverse Events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "measure": "Percentage of Participants Who Discontinue Due to AEs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 12 weeks"
            }
        ], 
        "removed_countries": {
            "country": "Belgium"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01656395"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of Days with Asthma Exacerbations", 
                "safety_issue": "No", 
                "time_frame": "Last 6 weeks of treatment"
            }, 
            {
                "measure": "Average Change from Baseline in Daytime Symptom Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and last six weeks of treatment"
            }, 
            {
                "measure": "Average Change from Baseline in Use of Short-Acting Beta-Agonists (SABAs)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and last six weeks of treatment"
            }, 
            {
                "measure": "Average Change from Baseline in Number of Nocturnal Awakenings", 
                "safety_issue": "No", 
                "time_frame": "Baseline and last six weeks of treatment"
            }, 
            {
                "measure": "Average Change from Baseline in Morning (AM) Peak Expiratory Flow (PEF)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and last six weeks of treatment"
            }, 
            {
                "measure": "Average Change from Baseline in Night (PM) Peak Expiratory Flow (PEF)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and last six weeks of treatment"
            }, 
            {
                "measure": "Change from Baseline in Asthma Quality of Life Questionnaire with Standardised Activities [AQLQ(S)] Overall and Domain Scores", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 12"
            }, 
            {
                "measure": "Percentage of Participants with a \u22650.5 Decrease in AQLQ(S) Overall and Domain Scores from Baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Change from Baseline in Asthma Control Questionnaire (ACQ) Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 12"
            }, 
            {
                "measure": "Percentage of Participants with a \u22650.5 decrease in ACQ Score from Baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Percentage of Participants with Asthma Attacks", 
                "safety_issue": "No", 
                "time_frame": "12 weeks of treatment"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}